Erasca股份在与AbbVie的合并传言中跳了60%, 在不确定的情况下跌至4.33美元。 Erasca shares jumped 60% on merger rumors with AbbVie, then fell to $4.33 amid uncertainty.

伊拉斯卡(Erasca)的股份在星期三暴涨了60%, Erasca shares surged 60% on Wednesday amid rumors of AbbVie's advanced talks to acquire Revolution Medicines, a cancer drug company, sparking investor speculation. 后来,随着市场消化不确定性,市场股票在星期四跌至4.33美元,官方交易没有确认。 The stock later dropped to $4.33 on Thursday as the market digested uncertainty, with no official deal confirmed. 以癌症治疗为重点的临床阶段生物技术Erasca报告说,第四季度的收入与预期一致,但分析家预测全年亏损。 Erasca, a clinical-stage biotech focused on cancer treatments, reported fourth-quarter earnings in line with expectations, but analysts project a full-year loss. 股票仍然波动不定,反映出市场对肿瘤部门合并传闻的敏感性更大。 The stock remains volatile, reflecting broader market sensitivity to merger rumors in the oncology sector.